688177 百奥泰
已收盘 06-12 15:00:01
资讯
新帖
简况
百奥泰：6月12日接受机构调研，自然人股东参与
证券之星 · 00:01
百奥泰：6月12日接受机构调研，自然人股东参与
百奥泰：公司于2026年5月11日参加科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会
证券之星 · 06-11 16:54
百奥泰：公司于2026年5月11日参加科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会
百奥泰：BAT2306（司库奇尤单抗）正在进行核准工艺和标准
证券之星 · 06-11 16:48
百奥泰：BAT2306（司库奇尤单抗）正在进行核准工艺和标准
百奥泰最新公告：BAT2206获得新加坡HSA上市批准
证券之星 · 06-10
百奥泰最新公告：BAT2206获得新加坡HSA上市批准
股市必读：百奥泰（688177）6月2日董秘有最新回复
证券之星 · 06-03
股市必读：百奥泰（688177）6月2日董秘有最新回复
百奥泰：BAT8006正在国内进行单药用于铂耐药卵巢癌适应症的关键注册III期临床试验
证券之星 · 06-02
百奥泰：BAT8006正在国内进行单药用于铂耐药卵巢癌适应症的关键注册III期临床试验
每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准
证券之星 · 05-24
每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准
百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书
智通财经 · 05-21
百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书
百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%
证券之星 · 05-20
百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%
百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™
美股速递 · 05-18
百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™
百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%
证券之星 · 05-18
百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%
百奥泰(688177.SH)：BAT2506获美国FDA上市批准
智通财经 · 05-18
百奥泰(688177.SH)：BAT2506获美国FDA上市批准
每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准
证券之星 · 05-17
每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准
百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%
证券之星 · 05-13
百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%
百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书
智通财经 · 05-12
百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
证券之星 · 05-06
百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%
每周股票复盘：百奥泰（688177）股东户数增7.75%
证券之星 · 05-02
每周股票复盘：百奥泰（688177）股东户数增7.75%
百奥泰（688177）2026年一季报简析：增收不增利
证券之星 · 04-29
百奥泰（688177）2026年一季报简析：增收不增利
图解百奥泰年报：第四季度单季净利润同比增长25.45%
证券之星 · 04-28
图解百奥泰年报：第四季度单季净利润同比增长25.45%
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
证券之星 · 04-26
每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":17.33,"timestamp":1781247601000,"preClose":16.88,"halted":0,"volume":2276331,"delay":0,"changeRate":0.0267,"floatShares":413999999,"shares":413999999,"eps":-0.943,"marketStatus":"已收盘","change":0.45,"latestTime":"06-12 15:00:01","open":16.88,"high":17.4,"low":16.72,"amount":38976200,"amplitude":0.0403,"askPrice":17.34,"askSize":33,"bidPrice":17.33,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.88,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":18.57,"lowLimit":15.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":32.02,"roa":"--","roe":"--","epsLYR":-0.8,"committee":-0.024043,"marketValue":7176000000,"turnoverRate":0.0055,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-15。","afterMarket":{"amount":0,"volume":0,"close":17.33,"buyVolume":0,"sellVolume":0,"time":1781249638866,"indexStatus":"已收盘 06-12 15:30:00","preClose":16.88},"floatMarketCap":7176000000},"requestUrl":"/m/hq/s/688177/","defaultTab":"news","newsList":[{"id":"2643926322","title":"百奥泰：6月12日接受机构调研，自然人股东参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2643926322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643926322?lang=zh_cn&edition=full","pubTime":"2026-06-13 00:01","pubTimestamp":1781280089,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年6月12日百奥泰发布公告称公司于2026年6月12日接受机构调研，自然人股东参与。目前 BT8006 已在开展铂耐药卵巢癌的 III 期研究，入组已过半。百奥泰主营业务：药物的研发、生产和销售。融资融券数据显示该股近3个月融资净流出691.88万，融资余额减少；融券净流出27.88万，融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061300000021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642400992","title":"百奥泰：公司于2026年5月11日参加科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2642400992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642400992?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:54","pubTimestamp":1781168056,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰06月11日在投资者关系平台上答复投资者关心的问题。公司于2026年5月11日在上海证券交易所上证路演中心参加了十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会暨召开2026年第一季度业绩说明会，说明会中对公司2025年年度及2026年第一季度的经营情况做了详细解读，公司也对投资者关注的问题做了回复并披露了投资者关系活动记录表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100026318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477","BK0239","159982","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642400563","title":"百奥泰：BAT2306（司库奇尤单抗）正在进行核准工艺和标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642400563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642400563?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:48","pubTimestamp":1781167705,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰(688177)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好。司库奇尤单抗是再次发补了吗？如果是，预计何时完成第二轮补充资料提交？如果不是，是什么原因导致NMPA审评暂停？百奥泰回复：尊敬的投资者您好！公司BAT2306（司库奇尤单抗）正在进行核准工艺和标准，新药上市申请的审批时间和过程具有不确定性，公司一直在积极跟进并推动相关进程。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100026197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442737","title":"百奥泰最新公告：BAT2206获得新加坡HSA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442737","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442737?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:44","pubTimestamp":1781084641,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司收到新加坡HSA签发的关于BAT2206(乌司奴单抗注射液)上市批准通知。该药品用于治疗中重度斑块状银屑病、活动性银屑病关节炎、中重度活动性克罗恩病等适应症。截至目前，BAT2206已获中国、美国、欧盟、新加坡、英国等地批准上市，商业化授权覆盖全球71个国家和地区。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000031579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640892852","title":"股市必读：百奥泰（688177）6月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640892852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640892852?lang=zh_cn&edition=full","pubTime":"2026-06-03 02:58","pubTimestamp":1780426691,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，百奥泰报收于18.39元，下跌3.92%，换手率0.8%，成交量3.3万手，成交额6136.28万元。董秘最新回复投资者： 去年8月交流会上表示BAT8006正在和FDA沟通国际临床。BAT8006正在国内进行单药用于铂耐药卵巢癌适应症的关键注册III期临床试验，感谢您对公司的关注！来自交易信息汇总：散户资金净流入835.76万元，占总成交额13.62%，表明中小投资者今日参与积极性较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300002795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640199219","title":"百奥泰：BAT8006正在国内进行单药用于铂耐药卵巢癌适应症的关键注册III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2640199219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640199219?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:24","pubTimestamp":1780392256,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰(688177)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：去年8月交流会上表示BAT8006正在和FDA沟通国际临床。相关沟通截止2026年5月是否有新的进展？预计何时会开启国际临床？百奥泰回复：尊敬的投资者您好！ BAT8006正在国内进行单药用于铂耐药卵巢癌适应症的关键注册III期临床试验，感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200033128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637375535","title":"每周股票复盘：百奥泰（688177）戈利木单抗获FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637375535","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637375535?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:27","pubTimestamp":1779564431,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，百奥泰报收于20.1元，较上周的19.58元上涨2.66%。本周关注点来自公司公告汇总：百奥泰戈利木单抗注射液获美国FDA上市批准，适应症为类风湿关节炎和溃疡性结肠炎。公司公告汇总百奥泰生物制药股份有限公司收到美国食品药品监督管理局通知，其戈利木单抗注射液已获准上市。BAT2206已获美国FDA和欧洲EMA批准上市，并在全球71个国家和地区达成商业化授权合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637892813","title":"百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637892813","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637892813?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:34","pubTimestamp":1779356051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到了国家药品监督管理局核准签发的关于乌司奴单抗注射液和乌司奴单抗注射液的《药品注册证书》。BAT2206是百奥泰根据NMPA、美国食品药品监督管理局、欧洲药品管理局生物类似药相关指导原则开发的乌司奴单抗注射液，乌司奴单抗是一款靶向白细胞介素IL-12和IL-23共有的 p40 亚基的全人源单克隆抗体。截至本公告披露日，BAT2206已获得FDA和EMA批准上市，美国注册商品名称为Starjemza，欧洲注册商品名为Usymro。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百奥泰(688177.SH)：艾沙力®/喜沙立®(乌司奴单抗注射液)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845313","title":"百奥泰（688177）披露2025年年度股东会决议公告，5月20日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845313?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:18","pubTimestamp":1779272303,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，百奥泰报收于19.57元，较前一交易日下跌1.16%，最新总市值为81.04亿元。百奥泰于近日披露《2025年年度股东会决议公告》。公告显示，公司于2026年5月19日召开2025年年度股东会，会议审议通过了《关于公司2025年年度报告及其摘要的议案》《关于公司2025年度董事会工作报告的议案》《关于公司2025年度利润分配预案的议案》等九项议案。出席会议的股东及代理人共131人，代表有表决权股份总数的70.3817%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110463142","title":"百奥泰戈利木单抗生物类似药获FDA批准 成Simponi®及Simponi Aria®首个生物类似药；Accord Biopharma将在美商业化Immgolis™与Immgolis Intri™","url":"https://stock-news.laohu8.com/highlight/detail?id=1110463142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110463142?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:00","pubTimestamp":1779105640,"startTime":"0","endTime":"0","summary":"百奥泰的戈利木单抗生物类似药已获得美国食品药品监督管理局（FDA）的批准，成为强生旗下Simponi®及Simponi Aria®的首个生物类似药。根据协议，Accord Biopharma将负责在美国市场商业化这两款产品，即Immgolis™（戈利木单抗-Sldi）与Immgolis Intri™（戈利木单抗-Sldi）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636027640","title":"百奥泰（688177）披露戈利木单抗注射液获美国FDA上市批准公告，5月18日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636027640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636027640?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:58","pubTimestamp":1779101895,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，百奥泰报收于19.46元，较前一交易日下跌0.61%，最新总市值为80.58亿元。该股当日开盘19.61元，最高19.63元，最低19.21元，成交额达3674.5万元，换手率为0.46%。近日，百奥泰生物制药股份有限公司披露关于Immgolis/ Immgolis Intri获美国FDA上市批准的公告。公告显示，公司收到美国食品药品监督管理局通知，其戈利木单抗注射液已获准上市。产品已获FDA和EMA批准，正在多个国家和地区申报上市，并已与多家企业达成商业化授权合作，覆盖118个国家和地区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800030119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636024622","title":"百奥泰(688177.SH)：BAT2506获美国FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636024622","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636024622?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:58","pubTimestamp":1779098337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到美国食品药品监督管理局签发的关于Immgolis/Immgolis Intri上市批准通知。据悉，BAT2506是百奥泰根据中国国家药品监督管理局、FDA、欧洲药品管理局生物类似药相关指导原则开发的戈利木单抗生物类似药。截至本公告披露日，BAT2506已获得FDA、EMA上市批准，美国商品名为Immgolis/Immgolis Intri，欧洲注册商品名为Gotenfia;已向NMPA、巴西国家卫生监督局等递交上市许可申请，目前正在评审中。BAT2506的商业化授权合作目前已覆盖118个国家和地区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","688177","IPOS","LABU","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636314062","title":"每周股票复盘：百奥泰（688177）注射用BAT8013获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636314062","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636314062?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:13","pubTimestamp":1778962389,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，百奥泰报收于19.58元，较上周的20.04元下跌2.3%。本周，百奥泰5月12日盘中最高价报20.78元。本周关注点公司公告汇总：百奥泰注射用BAT8013获药物临床试验批准，拟用于治疗晚期或转移性实体瘤。公司公告汇总：百奥泰召开2025年年度股东会，审议年度报告、利润分配预案等多项议案。百奥泰自愿披露关于注射用BAT8013获得药物临床试验批准通知书的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785302","title":"百奥泰（688177）披露2025年年度股东会会议资料，5月13日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635785302?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:34","pubTimestamp":1778668475,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，百奥泰报收于20.05元，较前一交易日下跌0.79%，最新总市值为83.02亿元。该股当日开盘20.38元，最高20.38元，最低19.74元，成交额达4893.29万元，换手率为0.59%。百奥泰于2026年5月13日披露《2025年年度股东会会议资料》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634978022","title":"百奥泰(688177.SH)注射用BAT8013获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2634978022","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634978022?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:02","pubTimestamp":1778580137,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品注射用BAT8013用于治疗晚期或转移性实体瘤患者的临床试验申请获得批准。BAT8013通过与细胞表面的CD25特异性结合，经受体介导的内吞作用进入细胞内部，在溶酶体环境中，其连接子被组织蛋白酶切割，释放出细胞毒载荷Exatecan。该机制既能选择性清除肿瘤微环境中的调节性T细胞，改善肿瘤免疫抑制微环境，也能直接杀伤CD25肿瘤细胞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633390184","title":"百奥泰（688177）披露关于转让药品品种权益及相关资产与业务的议案获通过，5月6日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633390184","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633390184?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:50","pubTimestamp":1778064627,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，百奥泰报收于20.23元，较前一交易日下跌1.8%，最新总市值为83.77亿元。公告显示，公司于2026年4月30日召开第二次临时股东会，审议通过了《关于转让药品品种权益及相关资产与业务的议案》。出席会议的股东及代理人共114人，代表有表决权股份288,959,575股，占公司总表决权股份的69.7835%。该议案为普通决议议案，已获出席会议股东所持有效表决权过半数通过，表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640905","title":"每周股票复盘：百奥泰（688177）股东户数增7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632640905?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:52","pubTimestamp":1777668729,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，百奥泰报收于20.6元，较上周的22.22元下跌7.29%。本周，百奥泰4月27日盘中最高价报22.58元。业绩披露要点：2026年一季报显示，百奥泰归母净利润为-1.52亿元，同比下降62.68%。股本股东变化截至2026年3月31日，百奥泰股东户数为9898.0户，较2025年12月31日增加712.0户，增幅7.75%。表决结果为同意285,349,592股，占98.7507%；反对3,606,883股，占1.2482%；弃权3,100股，占0.0011%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631741530","title":"百奥泰（688177）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2631741530","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631741530?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:53","pubTimestamp":1777420434,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百奥泰发布2026年一季报。根据财报显示，百奥泰增收不增利。其中，毛利率81.34%，同比增5.65%，净利率-60.35%，同比减33.57%，销售费用、管理费用、财务费用总计9730.62万元，三费占营收比38.68%，同比增3.41%，每股净资产0.54元，同比减63.54%，每股经营性现金流0.11元，同比减42.59%，每股收益-0.37元，同比减60.87%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-35.49%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900024272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319027","title":"图解百奥泰年报：第四季度单季净利润同比增长25.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319027","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630319027?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:45","pubTimestamp":1777311959,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2025年年报显示，当年度公司主营收入9.35亿元，同比上升25.84%；归母净利润-3.32亿元，同比上升34.95%；扣非净利润-4.26亿元，同比上升23.38%；其中2025年第四季度，公司单季度主营收入2.52亿元，同比上升55.58%；单季度归母净利润-1.08亿元，同比上升25.45%；单季度扣非净利润-1.47亿元，同比上升2.65%；负债率83.56%，投资收益83.39万元，财务费用1748.1万元，毛利率78.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800004856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630480802","title":"每周股票复盘：百奥泰（688177）拟4.5亿元转让贝塔宁品种权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630480802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630480802?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:20","pubTimestamp":1777152023,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，百奥泰报收于22.22元，较上周的23.03元下跌3.52%。本周，百奥泰4月20日盘中最高价报23.27元。本周关注点公司公告汇总：百奥泰拟向乐普药业转让贝塔宁品种权益及相关资产，交易总金额为4.5亿元。公司公告汇总百奥泰生物制药股份有限公司拟向乐普药业股份有限公司转让贝塔宁品种权益及相关资产与业务，交易总金额（含税）为人民币4.5亿元，分五期支付，并按年度净销售额的个位数百分比收取销售分成，最长分成期为10年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781364394299,"stockEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.1357},{"period":"3month","weight":-0.2218},{"period":"6month","weight":-0.2715},{"period":"1year","weight":-0.3691},{"period":"ytd","weight":-0.2511}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9898人(较上一季度增加7.75%)","perCapita":"41834股","listingDate":"2020-02-21","address":"广东省广州市黄埔区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是自身免疫药物、抗肿瘤药物。公司被认定为国家高新技术企业、国家工业企业知识产权运用试点企业、国家知识产权优势企业、广东省新型研发机构、广东省工程技术研究中心、广东省工程实验室、广东省企业技术中心、广东省制造业单项冠军企业。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}